Ji Sung, Rosenbloom Michael
Memory and Brain Wellness Center, University of Washington, Seattle, WA, USA.
Alzheimers Res Ther. 2024 Dec 19;16(1):265. doi: 10.1186/s13195-024-01640-3.
Report a case of an apolipoprotein E (APOE)ε2 carrier receiving lecanemab who developed late onset intracerebral hemorrhage (ICH) following amyloid-related imaging abnormalities-hemorrhage (ARIA-H).
We detail the history and neuroimaging findings of a 73-year-old male with Alzheimer's disease (APOEε2/ε3 status) who developed ICH after mild ARIA-H and suffering a fall.
The patient developed mild ARIA-H after his 13th infusion that was proceeded by left temporo-occipital hemorrhage following his 14th infusion.
Although APOE ε2 is known to be protective against Alzheimer's disease, it has also been shown to increase risk for hemorrhage with cerebral amyloid angiopathy. This case serves as an opportunity to examine the complex role that APOE ε2 plays in both protection against Alzheimer's disease and contribution to increased hemorrhagic risk with lecanemab.
报告1例载脂蛋白E（APOE）ε2携带者接受lecanemab治疗后，出现与淀粉样蛋白相关的影像异常-出血（ARIA-H）后发生迟发性脑出血（ICH）的病例。
我们详细介绍了1例73岁阿尔茨海默病男性（APOEε2/ε3状态）的病史和神经影像学检查结果，该患者在轻度ARIA-H后发生跌倒，继而出现ICH。
患者在第13次输注后出现轻度ARIA-H，在第14次输注后出现左侧颞枕部出血。
虽然已知APOE ε2对阿尔茨海默病有保护作用，但也已表明它会增加脑淀粉样血管病出血的风险。该病例为研究APOE ε2在预防阿尔茨海默病以及增加lecanemab出血风险中所起的复杂作用提供了契机。
